Enrique Alvarez, MD
Neurology · Aurora, CONPI 1790822054
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $284,205 of the $407,240 with a category attached, or 69.8%. It is spread thinly across 24 manufacturers, the largest accounting for just 22.5%. Among neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 723 payments — averaging $563.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$92K
- Genentech USA, Inc.$74K
- Biogen$54K
- Novartis$39K
- TG Therapeutics, Inc.$29K
- EMD Serono, Inc.$21K
- plus $99K from 18 others
Across 308 payments — averaging $45,666 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$8.3M
- Genentech, Inc.$2M
- E.r. Squibb & Sons, L.L.C.$2M
- Biogen$901K
- Sanofi$345K
- TG Therapeutics, Inc.$143K
- plus $345K from 8 others
What the payments were for
- Consulting fees$284,20570%
- Speaking & faculty fees$48,26712%
- Travel & lodging$44,17011%
- Food & beverage$29,3897%
- Education$1,2100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 88 | $91,700 |
| Genentech USA, Inc. | 92 | $74,111 |
| Biogen | 89 | $53,832 |
| Novartis | 134 | $39,283 |
| TG Therapeutics, Inc. | 70 | $28,805 |
| EMD Serono, Inc. | 69 | $20,585 |
| Novartis Pharma AG | 10 | $18,309 |
| Amgen(2 entities) | 38 | $17,632 |
| AstraZeneca | 27 | $14,569 |
| E.r. Squibb & Sons, L.L.C. | 10 | $14,481 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $12,600 |
| Bristol Myers Squibb | 61 | $4,093 |
| F. Hoffmann-la Roche AG | 5 | $3,472 |
| Merck Kgaa | 1 | $3,225 |
| Janssen Global Services, LLC | 4 | $3,129 |
| Greenwich Biosciences, Inc. | 1 | $2,856 |
| Mallinckrodt Hospital Products Inc. | 1 | $2,280 |
| Banner Life Sciences, LLC | 1 | $800 |
| Genentech, Inc. | 4 | $695 |
| Janssen Scientific Affairs, LLC | 5 | $347 |
| Actelion Pharmaceuticals, Ltd | 3 | $314 |
| Teva Pharmaceuticals USA, Inc. | 1 | $79 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Medtronic | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$407,240 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 23 | $290,471 |
| VumerityDiroximel Fumarate | 26 | $185,400 |
| ZeposiaOzanimod Hydrochloride | 17 | $152,362 |
| Dimethyl Fumarate | 40 | $111,025 |
| Dalfampridine ErDalfampridine | 155 | $56,282 |
| Modafinil | 59 | $22,570 |
| Nurtec OdtRimegepant Sulfate | 11 | $12,730 |
| LinzessLinaclotide | 13 | $11,145 |
| FingolimodFingolimod Hcl | 25 | $8,475 |
| Baclofen | 184 | $6,682 |
| Gabapentin | 158 | $4,139 |
| Carbamazepine ErCarbamazepine | 31 | $3,976 |
| Oxcarbazepine | 53 | $2,680 |
| Amitriptyline Hcl | 87 | $2,168 |
| Carbamazepine | 20 | $1,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $53,832 | $185,40026 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $14,481 | $152,36217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.
Other neurology in Aurora
- Jeffrey BennettAurora$605K
- Anna ShahAurora$157K
- Timothy VollmerAurora$136K
- Simon OhAurora$112K
- Amanda PiquetAurora$106K
- Brent MorelAurora$79K
- Drew KernAurora$68K
- Ondrea TimmermannAurora$33K
- Thomas RagoleAurora$31K
- Maria NagelAurora$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.